Linnemann B, Greinacher A, Lindhoff-Last E
J. W. Goethe University Hospital, Frankfurt / Main, Germany.
Vasa. 2010 Feb;39(1):103-7. doi: 10.1024/0301-1526/a000012.
The direct thrombin inhibitor lepirudin is mainly applied in heparin-induced thrombocytopenia. We report here the case of a 37-year-old kurdish woman in whom Behcets disease was diagnosed in 1998 when she presented with a Budd Chiari syndrome (BCS) complicated by pulmonary embolism. Recurrent venous thromboembolism (VTE) occurred despite anticoagulant therapy with UFH, LMWH or phenprocoumon and various immunosuppressive therapy regimens. In 2001, when BCS recurred ultimately i.v. lepirudin was administered. When the patient improved and remained clinically stable lepirudin was applied subcutaneously. During long-term treatment with twice-daily 50 mg no further VTE was observed over the following years. Additionally, no bleeding complications occurred. In May 2005 anticoagulant therapy was switched to phenprocoumon. BCS reoccurred when INR values were suboptimal in February 2007, and lepirudin treatment was immediately restarted. After admission the patient received 50 mg b.i.d. lepirudin s.c. with plasma levels in the therapeutic range (0.5-1.0 mg / l). Over the following months, lepirudin levels repeatedly exceeded the upper limit of this range and the dosage was stepwise reduced. Finally, 20 mg b.i.d. were sufficient to obtain therapeutic levels. Renal function was normal, but lepirudin antibodies were present in high titer, as assessed by ELISA. We suppose that these antibodies reduce renal filtration of lepirudin thus leading to increased plasma levels. This case is an example for successful long-term therapeutic-dose anticoagulation with s.c. lepirudin in a patient with Behcets disease and recurrent VTE despite therapeutic anticoagulant therapy with LMWH or vitamin K antagonists. However, frequent measurement of lepirudin plasma levels is needed. If stepwise dose lowering is required over time, the presence of lepirudin antibodies should be considered.
直接凝血酶抑制剂来匹卢定主要用于肝素诱导的血小板减少症。我们在此报告一例37岁的库尔德女性病例,该患者于1998年被诊断为白塞病,当时她出现布加综合征(BCS)并伴有肺栓塞。尽管使用普通肝素(UFH)、低分子肝素(LMWH)或苯丙香豆素进行抗凝治疗以及各种免疫抑制治疗方案,但仍反复发生静脉血栓栓塞(VTE)。2001年,当BCS最终复发时,静脉注射了来匹卢定。当患者病情改善并保持临床稳定时,改为皮下注射来匹卢定。在每日两次50毫克的长期治疗期间,在随后几年中未观察到进一步的VTE。此外,未发生出血并发症。2005年5月,抗凝治疗改为苯丙香豆素。2007年2月,当国际标准化比值(INR)值未达最佳时,BCS复发,立即重新开始来匹卢定治疗。入院后,患者皮下注射50毫克每日两次的来匹卢定,血浆水平在治疗范围内(0.5 - 1.0毫克/升)。在接下来的几个月中,来匹卢定水平多次超过该范围的上限,剂量逐步降低。最后,每日两次20毫克就足以达到治疗水平。肾功能正常,但通过酶联免疫吸附测定(ELISA)评估发现存在高滴度的来匹卢定抗体。我们推测这些抗体减少了来匹卢定的肾脏滤过,从而导致血浆水平升高。该病例是一个成功使用皮下注射来匹卢定进行长期治疗剂量抗凝的例子,该患者患有白塞病且尽管使用LMWH或维生素K拮抗剂进行治疗性抗凝仍反复发生VTE。然而,需要频繁测量来匹卢定血浆水平。如果随着时间推移需要逐步降低剂量,应考虑来匹卢定抗体